MND

Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP

Retrieved on: 
Friday, February 23, 2024
Fever, European Commission, EMA, ALS, Committee, MND, Myalgia, Intracranial pressure, BIIB, Cerebrospinal fluid, Pain, Hope, Biogen, European, SOD1, Arthralgia, Civil service commission, Biomarker, Fatigue, CHMP, AFL, European Medicines Agency, Protein, Disease, UZ Leuven, Mutation, Myelitis, Neurology, Aseptic meningitis, Research, Chronic pain, Vaccine

If authorized by the European Commission (EC), QALSODY will be the first treatment approved in the European Union to target a genetic cause of ALS, also known as motor neuron disease (MND).

Key Points: 
  • If authorized by the European Commission (EC), QALSODY will be the first treatment approved in the European Union to target a genetic cause of ALS, also known as motor neuron disease (MND).
  • “The CHMP’s positive opinion reinforces the impact QALSODY can have in SOD1-ALS and further demonstrates Biogen’s commitment to address the unmet needs of people living with ALS and neuromuscular diseases,” said Priya Singhal, M.D., M.P.H., Head of Development at Biogen.
  • Trends towards improvement in the physical abilities of participants who received QALSODY were seen compared to those who received placebo, as measured by the ALS Functional Ratings Scale-Revised (ALSFRS-R).
  • Serious neurologic events, including myelitis and/or radiculitis; papilledema and elevated intracranial pressure; and aseptic meningitis have also been reported.

Mandalay Resources Announces Normal Course Issuer Bid

Retrieved on: 
Friday, February 23, 2024
Acquisition, Bank of Montreal, MND, The Company, TSX, Toronto Stock Exchange, Calendar, Letter, CAD, Indian stock exchange, Security (finance)

TORONTO, Feb. 23, 2024 /PRNewswire/ - Mandalay Resources Corporation ("Mandalay" or "the Company") (TSX: MND) (OTCQB: MNDJF) announced today that the Toronto Stock Exchange (the "TSX") has approved its notice of intention to make a normal course issuer bid ("NCIB") for a portion of its common shares ("Common Shares").

Key Points: 
  • TORONTO, Feb. 23, 2024 /PRNewswire/ - Mandalay Resources Corporation ("Mandalay" or "the Company") (TSX: MND) (OTCQB: MNDJF) announced today that the Toronto Stock Exchange (the "TSX") has approved its notice of intention to make a normal course issuer bid ("NCIB") for a portion of its common shares ("Common Shares").
  • Mandalay may begin to purchase Common Shares on or about February 27, 2024.
  • The price that Mandalay will pay for any Common Shares will be the market price of such Common Shares at the time of acquisition.
  • Any Common Shares that are purchased under the NCIB will be cancelled upon their purchase by Mandalay.

Mandalay Resources Announces Normal Course Issuer Bid

Retrieved on: 
Friday, February 23, 2024
Acquisition, Bank of Montreal, MND, TSX, Toronto Stock Exchange, Calendar, Letter, CAD, Indian stock exchange, Security (finance)

TORONTO, Feb. 23, 2024 /PRNewswire/ -- Mandalay Resources Corporation ("Mandalay" or "the Company") (TSX: MND) (OTCQB: MNDJF) announced today that the Toronto Stock Exchange (the "TSX") has approved its notice of intention to make a normal course issuer bid ("NCIB") for a portion of its common shares ("Common Shares").

Key Points: 
  • TORONTO, Feb. 23, 2024 /PRNewswire/ -- Mandalay Resources Corporation ("Mandalay" or "the Company") (TSX: MND) (OTCQB: MNDJF) announced today that the Toronto Stock Exchange (the "TSX") has approved its notice of intention to make a normal course issuer bid ("NCIB") for a portion of its common shares ("Common Shares").
  • Mandalay may begin to purchase Common Shares on or about February 27, 2024.
  • The price that Mandalay will pay for any Common Shares will be the market price of such Common Shares at the time of acquisition.
  • Any Common Shares that are purchased under the NCIB will be cancelled upon their purchase by Mandalay.

Mandalay Resources Announces Financial Results for the Fourth Quarter and Full-Year 2023

Retrieved on: 
Thursday, February 22, 2024
Conversation, MND, Mining, Antimony, TSX, Growth, Safety, Consolidated, Gold, Costerfield, Hand, Cryptocurrency

TORONTO, Feb. 22, 2024 /PRNewswire/ - Mandalay Resources Corporation ("Mandalay" or the "Company") (TSX: MND) (OTCQB: MNDJF) is pleased to announce its financial results for the fourth quarter and year ended December 31, 2023.

Key Points: 
  • TORONTO, Feb. 22, 2024 /PRNewswire/ - Mandalay Resources Corporation ("Mandalay" or the "Company") (TSX: MND) (OTCQB: MNDJF) is pleased to announce its financial results for the fourth quarter and year ended December 31, 2023.
  • After a poor start in 2023 due to various operational issues mostly at Costerfield, our strong financial performance in the fourth quarter underscored the effectiveness of our various strategic initiatives and the increased operational and financial focus of our team.
  • "Costerfield delivered a robust financial quarter, achieving $28.5 million in revenue and generating $17.0 million in adjusted EBITDA.
  • The following table summarizes the Company's consolidated financial results for the three months and years ended December 31, 2023 and 2022:

Mandalay Resources Announces Financial Results for the Fourth Quarter and Full-Year 2023

Retrieved on: 
Thursday, February 22, 2024
The Company, Conversation, MND, Mining, Antimony, TSX, Growth, Safety, Consolidated, Gold, Costerfield, Hand, Cryptocurrency

TORONTO, Feb. 22, 2024 /PRNewswire/ -- Mandalay Resources Corporation ("Mandalay" or the "Company") (TSX: MND) (OTCQB: MNDJF) is pleased to announce its financial results for the fourth quarter and year ended December 31, 2023.

Key Points: 
  • TORONTO, Feb. 22, 2024 /PRNewswire/ -- Mandalay Resources Corporation ("Mandalay" or the "Company") (TSX: MND) (OTCQB: MNDJF) is pleased to announce its financial results for the fourth quarter and year ended December 31, 2023.
  • After a poor start in 2023 due to various operational issues mostly at Costerfield, our strong financial performance in the fourth quarter underscored the effectiveness of our various strategic initiatives and the increased operational and financial focus of our team.
  • "Costerfield delivered a robust financial quarter, achieving $28.5 million in revenue and generating $17.0 million in adjusted EBITDA.
  • The following table summarizes the Company's consolidated financial results for the three months and years ended December 31, 2023 and 2022:

Mandalay Resources Provides Target Release Date for Fourth Quarter and Full-Year 2023 Financial Results and Conference Call

Retrieved on: 
Thursday, February 15, 2024
TSX, MND, Internet service provider

TORONTO, Feb. 15, 2024 /PRNewswire/ -- Mandalay Resources Corporation ("Mandalay" or "the Company") (TSX: MND) (OTCQB: MNDJF) today announced that its fourth quarter and full-year 2023 financial results will be released after market close on February 22, 2024, followed by a conference call with Frazer Bourchier, President and Chief Executive Officer of Mandalay, for investors and analysts on February 23, 2024, at 8:00 AM (Toronto time).

Key Points: 
  • TORONTO, Feb. 15, 2024 /PRNewswire/ -- Mandalay Resources Corporation ("Mandalay" or "the Company") (TSX: MND) (OTCQB: MNDJF) today announced that its fourth quarter and full-year 2023 financial results will be released after market close on February 22, 2024, followed by a conference call with Frazer Bourchier, President and Chief Executive Officer of Mandalay, for investors and analysts on February 23, 2024, at 8:00 AM (Toronto time).
  • Analysts and interested investors may join by using the following dial-in number:
    A replay of the conference call will be available until 11:59 PM (Toronto time), March 01, 2024, and can be accessed using the following dial-in numbers:

Mandalay Resources Provides Target Release Date for Fourth Quarter and Full-Year 2023 Financial Results and Conference Call

Retrieved on: 
Thursday, February 15, 2024
TSX, MND, The Company, Internet service provider

TORONTO, Feb. 15, 2024 /PRNewswire/ - Mandalay Resources Corporation ("Mandalay" or "the Company") (TSX: MND) (OTCQB: MNDJF) today announced that its fourth quarter and full-year 2023 financial results will be released after market close on February 22, 2024, followed by a conference call with Frazer Bourchier, President and Chief Executive Officer of Mandalay, for investors and analysts on February 23, 2024, at 8:00 AM (Toronto time).

Key Points: 
  • TORONTO, Feb. 15, 2024 /PRNewswire/ - Mandalay Resources Corporation ("Mandalay" or "the Company") (TSX: MND) (OTCQB: MNDJF) today announced that its fourth quarter and full-year 2023 financial results will be released after market close on February 22, 2024, followed by a conference call with Frazer Bourchier, President and Chief Executive Officer of Mandalay, for investors and analysts on February 23, 2024, at 8:00 AM (Toronto time).
  • Analysts and interested investors may join by using the following dial-in number:
    A replay of the conference call will be available until 11:59 PM (Toronto time), March 01, 2024, and can be accessed using the following dial-in numbers:

Mandalay Resources Announces Appointment of Hashim Ahmed as EVP and Chief Financial Officer

Retrieved on: 
Tuesday, February 6, 2024
PwC, Growth, MND, CFO, Financial management, History, TSX, Mining, LLP, Barrick Gold, Management

TORONTO, Feb. 6, 2024 /PRNewswire/ - Mandalay Resources Corporation ("Mandalay" or the "Company") (TSX: MND) (OTCQB: MNDJF) is pleased to announce the appointment of Hashim Ahmed as its new Executive Vice President and Chief Financial Officer (CFO), effective March 1, 2024.

Key Points: 
  • TORONTO, Feb. 6, 2024 /PRNewswire/ - Mandalay Resources Corporation ("Mandalay" or the "Company") (TSX: MND) (OTCQB: MNDJF) is pleased to announce the appointment of Hashim Ahmed as its new Executive Vice President and Chief Financial Officer (CFO), effective March 1, 2024.
  • As previously announced, current CFO Nick Dwyer resigned for personal reasons and will be supporting the transition to Mr. Ahmed.
  • His extensive industry experience, focus on capital discipline and strategic financial acumen make him an ideal fit for our leadership team.
  • As we embark on our next phase of growth, Hashim will play a crucial role in steering our financial strategies and ensuring our continued financial success."

Mandalay Resources Announces Appointment of Hashim Ahmed as EVP and Chief Financial Officer

Retrieved on: 
Tuesday, February 6, 2024
PwC, Growth, MND, CFO, Financial management, History, TSX, Mining, The Company, LLP, Barrick Gold, Management

TORONTO, Feb. 6, 2024 /PRNewswire/ -- Mandalay Resources Corporation ("Mandalay" or the "Company") (TSX: MND) (OTCQB: MNDJF) is pleased to announce the appointment of Hashim Ahmed as its new Executive Vice President and Chief Financial Officer (CFO), effective March 1, 2024.

Key Points: 
  • TORONTO, Feb. 6, 2024 /PRNewswire/ -- Mandalay Resources Corporation ("Mandalay" or the "Company") (TSX: MND) (OTCQB: MNDJF) is pleased to announce the appointment of Hashim Ahmed as its new Executive Vice President and Chief Financial Officer (CFO), effective March 1, 2024.
  • As previously announced, current CFO Nick Dwyer resigned for personal reasons and will be supporting the transition to Mr. Ahmed.
  • His extensive industry experience, focus on capital discipline and strategic financial acumen make him an ideal fit for our leadership team.
  • As we embark on our next phase of growth, Hashim will play a crucial role in steering our financial strategies and ensuring our continued financial success."

Metabolon and Sheffield Institute for Translational Neuroscience Join Forces to Propel ALS Research and Biomarker Discovery

Retrieved on: 
Tuesday, January 23, 2024
Patient, MNDA, Research, MND, Partnership, Metabolomics, CSF, Translational neuroscience, University, Brain cell, Medicine, Motor neuron diseases, Cell, Plasma, Disease, Facial muscles, Fluid mechanics, Biomarker, Neurology, Nervous system, Metabolism, Diagnosis, Motor Neurone Disease Association, Pharmaceutical industry

MORRISVILLE, N.C., Jan. 23, 2024 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life science research, diagnostic, therapeutic development, and precision medicine applications, today announced a strategic partnership with the Sheffield Institute for Translational Neuroscience (SITraN) and A Multicentre Biomarker Resource Strategy in ALS (AMBRoSIA). The collaboration aims to explore novel pathogenic mechanisms of ALS that may expand therapeutic possibilities to a patient population in need of additional treatment options.

Key Points: 
  • Motor neuron diseases (MND), which include ALS, are progressive disorders that affect voluntary muscle control.
  • Currently, there is no cure for these diseases, and approximately 80% of people with ALS die within two to five years of diagnosis.
  • "Metabolon is thrilled to collaborate with SITraN, a leading institution in translational neuroscience, and AMBRoSIA.
  • Together, we aim to drive significant progress in ALS research and biomarker discovery, bringing us closer to effective diagnostic and therapeutic solutions for this challenging disease," said Karl Bradshaw, Chief Business Officer at Metabolon.